National Resilience Institute

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Therapy, ICI, RECIST, University, National Resilience Institute, Disease, Patient, IL15, Monroe Dunaway Anderson, Neoplasm, DCR, ORR, Melanoma, IL2, CTMC, MD Anderson Cancer Center, TIL, Pharmaceutical industry, Obsidian

OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.

Key Points: 
  • OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.
  • , professor of Melanoma Medical Oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.
  • “The OBX-115 data show its potential to be a meaningful advancement in the treatment of metastatic melanoma and TIL cell therapy,” said Parameswaran Hari, M.D., M.S., Chief Development Officer of Obsidian Therapeutics.
  • “These positive results underscore the potential for OBX-115 TIL cell therapy to offer patients with metastatic melanoma a differentiated TIL therapy without the need for IL2,” said Madan Jagasia, M.D., M.S., CEO of Obsidian Therapeutics.

Resilience Appoints Bill Marth as President of Services

Retrieved on: 
Tuesday, November 7, 2023
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Sale, GTCR, MBA, National Resilience Institute, Multimedia, AMRI, Patient, Management, Resilience

National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services.

Key Points: 
  • National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services.
  • View the full release here: https://www.businesswire.com/news/home/20231107738739/en/
    In this role, Mr. Marth will have end-to-end responsibility for all development and manufacturing services and commercial activities at Resilience.
  • Resilience’s objective in creating the new Services organization is to strengthen the company’s focus on providing the highest quality execution for pre-clinical, clinical and commercial programs.
  • “We look forward to benefitting from his experience and capability to better serve our customers and further scale Resilience.”

Italy Power Rental Market Assessment & Forecast Report, 2022-2023 & 2023-2029 with Competitive Analysis of Key Vendors - United Rentals, Aggreko, Loxam, Caterpillar, Atlas Copco, Cummins, & KOHLER - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023
Other Energy, Energy, Liquefied natural gas, Atlas Copco, PMP, European Rental Association, Caput Mundi, Housing, Coal, Rail transport by country, Microsoft, Electricity, National Resilience Institute, Carbon footprint, Winter, City, Transport, Cummins, Privacy, USD, Friuli, Video game, Renewable energy, Tourism, Commercial property, LNG, Aggreko, Caterpillar

The "Italy Power Rental Market - Strategic Assessment & Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Italy Power Rental Market - Strategic Assessment & Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.
  • What are some significant growth opportunities in the Italy power rental market?
  • Which fuel type is projected to dominate the Italy power rental market?
  • Which are the key vendors in the Italy power rental market?

Resilience Lab New Evidence-Informed Group Therapy Expands Mental Health Access and Allows for Insurance Coverage

Retrieved on: 
Thursday, October 5, 2023
COVID-19, Anxiety, Columbia University Irving Medical Center, Gold, Insurance, Columbia University, Private practice, Mental, EMR, Mental health, National Resilience Institute, Depression, Health care, Nursing

The country is facing a severe lack of mental health care providers, with more than 150 million people living in federally designated mental health professional shortage areas.

Key Points: 
  • The country is facing a severe lack of mental health care providers, with more than 150 million people living in federally designated mental health professional shortage areas.
  • Group therapy expands access to mental health services and reduces wait times for those seeking treatment.
  • Group therapy can increase the effectiveness of individual therapy or provide an alternative treatment for individuals who are struggling.
  • "Group therapy is a bonafide, standalone treatment that has a considerable benefit for those being treated for mental health disorders.

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

Retrieved on: 
Tuesday, October 3, 2023
Canavan disease, Partnership, PALO, CAH, Congenital adrenal hyperplasia, Hope, AAV, National Resilience Institute, Patient, SAN, Cancer, DSM-IV codes, Medical device, Pharmaceutical industry, Resilience

Under the terms of the collaboration, BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites.

Key Points: 
  • Under the terms of the collaboration, BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites.
  • “Our partnership with BridgeBio seeks to accelerate development of innovative therapeutic options for patients in need,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.
  • “Manufacturing is the most critical and costly aspect of developing gene therapy for patients with a serious unmet need.
  • “We appreciate the opportunity to collaborate with the experienced and knowledgeable team at Resilience on the manufacturing of our gene therapies.

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

Retrieved on: 
Tuesday, October 3, 2023
Other Manufacturing, Genetics, Chemicals, Plastics, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Canavan disease, Partnership, CAH, Congenital adrenal hyperplasia, Hope, Multimedia, AAV, National Resilience Institute, Patient, Cancer, Pharmaceutical industry, Medical device, Resilience

Under the terms of the collaboration, BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites.

Key Points: 
  • Under the terms of the collaboration, BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites.
  • “Our partnership with BridgeBio seeks to accelerate development of innovative therapeutic options for patients in need,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.
  • “Manufacturing is the most critical and costly aspect of developing gene therapy for patients with a serious unmet need.
  • “We appreciate the opportunity to collaborate with the experienced and knowledgeable team at Resilience on the manufacturing of our gene therapies.

KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapies for the Treatment of Solid Tumors

Retrieved on: 
Wednesday, September 6, 2023
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, SOCS1, CTMC, Partnership, TIL, KSQ, Etiler, National Resilience Institute, Patient, Engineering, PD-1, Therapy, IND, MD Anderson Cancer Center, Tumor microenvironment, Pharmaceutical industry, Vaccine

"Our eTIL programs – which edit the SOCS1 and Regnase-1 genes – have the potential to be first- and best-in-class cell therapies for cancer treatment.

Key Points: 
  • "Our eTIL programs – which edit the SOCS1 and Regnase-1 genes – have the potential to be first- and best-in-class cell therapies for cancer treatment.
  • As our eTIL programs move through IND-enabling studies, our partnership with CTMC will have us ready to manufacture KSQ-001EX and KSQ-004EX for clinical studies," said Qasim Rizvi, Chief Executive Officer of KSQ.
  • "We believe our eTIL programs have the potential to address the significant unmet need in the solid tumor space."
  • "TIL therapies have tremendous potential for the treatment of solid tumors as they are naturally selected to target a host of tumor antigens specific to the patient.

Resilience Announces Joint Venture with Lifera to Develop Manufacturing Facility in Saudi Arabia

Retrieved on: 
Monday, August 28, 2023
Supply Chain Management, General Health, Pharmaceutical, Infectious Diseases, Other Manufacturing, Genetics, Retail, Chemicals, Plastics, Biotechnology, Stem Cells, Manufacturing, Health, Workforce, Public Investment Fund, Therapy, Education, GCC, Messenger, Plasma, National Resilience Institute, Dicarboxylic acid, CGMP, Patient, Ecosystem, Fine chemical, Resilience

Through this strategic joint venture and working with Lifera, Resilience would provide expertise for the design, construction and commission of a cGMP state-of-the-art drug product manufacturing facility.

Key Points: 
  • Through this strategic joint venture and working with Lifera, Resilience would provide expertise for the design, construction and commission of a cGMP state-of-the-art drug product manufacturing facility.
  • The joint venture will be focused on sterile injectables and other parenteral products, fulfilling existing local and regional demand.
  • Resilience will support the training of up to 200 Lifera staff and Lifera will explore the establishment of dedicated training facilities in Saudi Arabia to support the workforce training and upskilling for the joint venture.
  • “We are honored to partner with Lifera to strengthen Saudi Arabia’s life sciences ecosystem,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.

Resilience Lab Enlists VP of People to Renew Focus on Person-Centric Culture

Retrieved on: 
Thursday, August 24, 2023
Burnout, Communication, Education, Culture, The People's Operator, Feedback, Head, Curriculum, Policy, National Resilience Institute, Finix Comics, HR, Growth, Banares, Nursing, Management

The move is aimed at delivering a strong foundation for Resilience Lab as the company continues hiring new clinicians across the Northeast.

Key Points: 
  • The move is aimed at delivering a strong foundation for Resilience Lab as the company continues hiring new clinicians across the Northeast.
  • Resilience Lab has doubled down on addressing the needs of its employees through the development, support and education of its clinicians.
  • By putting into place procedures that are aimed at openness, communication and feedback, Resilience Lab is looking to take its growth to the next level.
  • Prior to joining Resilience Lab, James served as Head of People at StreamNative, Head of People at Finix, and VP of People Operations at Valimail.

Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, August 9, 2023
BioNTech, CT, Nephrotoxicity, IV, Diabetes, Hospital, Mucor, Conference call, Clinical trial, Women's Hospital International and Fertility Centre, Infection, Brain, LNC, Research, Biomedical Research, European Congress of Ethnic Religions, Messenger, Lung, Acute myeloid leukemia, Development, MRI, Kidney, National Resilience Institute, ECCMID, MD, Patient, Standard of care, Azole, Microsoft Access, RNA interference, Fungal infection, FDA, Nationwide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Conference, NYSE, Food, Female, Pharmaceutical industry, Medical imaging, Antifungal

BEDMINSTER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) --  Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

Key Points: 
  • Matinas’ collaboration with National Resilience continues to focus on in vitro and in vivo delivery of mRNA and expects initial data later in 2023.
  • The Company reported no revenue for the second quarter of 2023 compared with $1.1 million of revenue for the second quarter of 2022, which was generated from the Company’s research collaborations with BioNTech SE.
  • Total costs and expenses for the second quarter of 2023 were $6.2 million compared with $7.0 million for the second quarter of 2022.
  • The net loss for the second quarter of 2023 was $6.1 million, or $0.03 per share, compared with a net loss for the second quarter of 2022 of $5.9 million, or $0.03 per share.